Grifols (GRFS) Q3 2026 Earnings Call Transcript

Grifols reported Q3 2026 revenue of €2.04 billion, up 8.4% at constant currency, and adjusted EBITDA of €538 million, up 9.8%, with the margin expanding 60 bps to 26.4%. Nine-month free cash flow before M&A rose 59% year over year to €298 million, and net leverage fell to 3.98x; management reiterated its 2026 guidance and the Board approved an interim dividend of €0.15 per share. Growth was offset by China albumin weakness and a 7% nine-month Diagnostics revenue decline following the QuidelOrtho joint business dissolution; management also expects more modest Biopharma growth in Q4 and does not expect an update on a potential U.S. Biopharma IPO until 2027.

Analysis

GRFS’s earnings quality is improving, but the investment case is shifting from “growth” to proof that growth converts into durable cash and lower debt. Q3’s margin progress is encouraging; however, nine-month free cash flow benefited from timing, and management expects some unwind in Q4. The key near-term test is therefore cash conversion and year-end leverage—not another strong revenue-growth headline. A miss on cash generation would weaken the deleveraging narrative even if adjusted EBITDA holds up.

Over 1–3 months, expect the Q4 comparison to moderate reported Biopharma growth, while China albumin inventory clearance remains difficult to verify: management does not know competitors’ channel stocks, limiting visibility on the recovery timetable. Across 6–18 months, Egypt could improve sourcing flexibility and economics, but the margin contribution is still early and company claims require validation in plasma costs and gross margin. A U.S. Biopharma IPO is potential value-unlock optionality, not a base-case catalyst; management does not expect an update until 2027.

The contrarian risk is that subcutaneous IG growth and strong demand mask constrained volume choices and a less favorable “last liter” economics trade-off as albumin stays weak. EMA/FDA scrutiny is industry-wide, not GRFS-specific on the information provided, but adverse-event actions could affect the whole plasma-derived IG category, including competitors such as CSL and Takeda. A broad safety signal or meaningful label/access change would challenge the growth thesis. The balance sheet has improved, but leverage remains material; the dividend and any IPO proceeds should not be treated as substitutes for sustained organic debt reduction.

Key Decisions for Investors

• Do not chase the Q3 growth print. Treat GRFS as a conditional hold/watch; consider adding only after Q4 confirms full-year cash-flow guidance and further organic deleveraging. Falsify the improving-credit thesis if cash conversion materially reverses or leverage stops declining despite EBITDA growth.
• Track China albumin sell-through versus reported sell-in, pricing, and inventory commentary over the next two quarters. Do not underwrite a rapid recovery from early sell-through improvement alone; a renewed deterioration in demand or continued inventory overhang into 2027 would weigh on Biopharma mix and margins.
• Treat the potential U.S. Biopharma IPO and Egypt sourcing benefits as upside options, not core valuation support. Reassess when there is transaction detail or reported evidence of lower plasma cost per liter; monitor the late-Q4 SPARTA readout and Q1 2027 presentation as a separate, binary Alpha-1 catalyst.
• Monitor EMA/FDA communications for specific safety actions, not merely industry scrutiny. A product-wide label, prescribing, or access change is a downside catalyst for GRFS and plasma-derived IG peers; absent such action, avoid assuming the review is a company-specific earnings event.